Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LAT1 Double Nickase Plasmid (h): sc-401609-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LAT1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- LAT1 Double Nickase Plasmid (h) and LAT1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting SLC7A5. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LAT1 Antibody (D-10): sc-374232
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LAT1 Double Nickase Plasmid (h) | sc-401609-NIC | 20 µg | $410.00 |
SLC7A5 encodes the L-type amino acid transporter 1 (LAT1), a sodium-independent system L transporter that forms a heterodimer with SLC3A2 (CD98hc) to mediate uptake of large neutral essential amino acids such as leucine, phenylalanine, and tyrosine. By regulating intracellular amino acid availability, LAT1 influences nutrient-sensing programs including mTORC1 signaling, translational control, and cellular metabolic adaptation. LAT1 activity supports proliferative and stress-response states by coupling amino acid transport to redox and bioenergetic demands, linking membrane transport to growth-factor and oncogenic signaling networks. Altered SLC7A5 expression and amino acid transport capacity have been associated with dysregulated metabolism in cancer biology and with neurodevelopmental and neurological phenotypes where amino acid flux impacts neurotransmitter precursors and cellular homeostasis.
LAT1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the SLC7A5 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within SLC7A5. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt SLC7A5 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of SLC7A5-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.